WARMINSTER, Pa. , Aug. 05, 2020 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on developing a cure for people with chronic hepatitis B virus (HBV) infection, as well as therapies to treat coronaviruses (including...

WARMINSTER, Pa. , July 29, 2020 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on developing a cure for people with chronic hepatitis B virus (HBV) infection, as well as therapies to treat coronaviruses (including...

WARMINSTER, Pa. , May 27, 2020 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company focused on developing a cure for people with chronic hepatitis B virus (HBV) infection, today announced that William Collier , Arbutus’ President and Chief...

  Mean 60 mg HBsAg reduction of 0.99 log10 IU/mL at week 12, with normal ALT and AST values throughout the follow-up period 90 mg single-dose and 60 mg multi-dose cohorts initiated with data expected in the second half of 2020 Conference Call and Webcast Scheduled Today at 4:30 PM ET WARMINSTER,...

WARMINSTER, Pa. , May 12, 2020 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company focused on developing a cure for people with chronic hepatitis B virus (HBV) infection, today announced that William Collier , Arbutus’ President and Chief...

Arbutus remains on track to achieve its key 2020 objectives despite COVID-19 challenges Conference Call and Webcast Scheduled Today at 8:00 AM ET WARMINSTER, Pa. , May 11, 2020 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company focused on...

WARMINSTER, Pa. , May 04, 2020 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a Hepatitis B Virus (HBV) therapeutic solutions company, today announced that it has scheduled its first quarter financial results, conference call and webcast for Monday, May 11, 2020 ....

Positive single dose AB-729 data in chronic hepatitis B subjects supports  further clinical development First multiple dose cohort results expected in second half of 2020 One or more additional single dose cohorts planned to further optimize antiviral response and dosing frequency with results...

Conference Call and Webcast Scheduled Today at 8:45 AM ET WARMINSTER, Pa. , March 05, 2020 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a Hepatitis B Virus (HBV) therapeutic solutions company, today reports its fourth quarter and year end 2019 financial results, confirms 2020...

WARMINSTER, Pa. , Feb. 27, 2020 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a Hepatitis B Virus (HBV) therapeutic solutions company, today announced that it has scheduled its fourth quarter and Year-End 2019 financial results, conference call and webcast for Thursday, March 5,...